Commission decision: legal act granting a centralised marketing authorisation

A Commission decision is the legally binding act by which the European Commission grants, varies or refuses a centralised marketing authorisation.

Also known as: Commission implementing decision, European Commission decision, EC decision

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 10 of Regulation (EC) No 726/2004
Timeline
About 67 days after the CHMP opinion
Consulted
Standing Committee on Medicinal Products for Human Use
Effect
One authorisation valid in every Member State, entered in the Union Register

How it works

The CHMP opinion is a scientific recommendation; the marketing authorisation itself is granted by the European Commission. Under Article 10 of Regulation (EC) No 726/2004 the Commission prepares a draft decision within 15 days of receiving the opinion and sends it to the Member States and the applicant. The Standing Committee on Medicinal Products for Human Use, made up of Member State representatives, gives its opinion in writing: Member States have 22 days to send written observations and can ask for the draft to be discussed at a plenary meeting. The Commission then adopts the final decision, an implementing act, within 15 days. If a Member State's observations raise important new scientific or technical questions that the opinion did not address, the application goes back to EMA, and if the draft departs from the opinion the Commission must explain why.

The decision carries the product information as annexes, in all official EU languages, together with the conditions of the authorisation. The applicant therefore sends EMA the translations within days of the opinion, Member States review them, and the final texts go to the Commission with the opinion. Under Article 13 the authorisation is valid throughout the Union and confers the same rights and obligations in each Member State as a national authorisation. The product is entered in the Union Register of medicinal products and given a number that must appear on the packaging, and a notification of the authorisation is published in the Official Journal. Iceland and Norway grant corresponding national authorisations within 30 days of the decision.

Several dates run from the decision. The periods of data exclusivity and market protection for a centrally authorised product start on the date the decision is notified to the holder, which the Union Register publishes. EMA publishes the European public assessment report once the decision is adopted. The Commission also adopts decisions on major changes to a centralised authorisation, on refusals, which prohibit marketing of the product throughout the Union, and at the end of referral procedures, where the decision is addressed to the Member States.

What goes wrong

Planning the launch from the date of the CHMP opinion, when the product cannot be marketed until the decision is adopted; late or poor translations, which hold up the annexes; timing pricing and reimbursement filings around the opinion rather than the decision; and counting exclusivity periods from the opinion or the adoption date instead of the date of notification.

Timing

  1. Day 210

    CHMP adopts its opinion.

  2. Day 215

    Applicant sends the product information in all EU languages.

  3. Day 235

    Final translations after Member States' linguistic review.

  4. Day 237

    Opinion and annexes go to the Commission and the Standing Committee.

  5. Day 239 to 261

    Draft decision and Standing Committee consultation.

  6. Day 277

    Commission adopts the decision and notifies the holder.

EMA's standard timetable puts the opinion at Day 210 and the final decision at Day 277, about 67 days later. The applicant provides the product information in all languages by Day 215, Member States send linguistic comments by Day 229 and the applicant sends final translations by Day 235. EMA transmits the opinion and annexes to the Commission and the Standing Committee at Day 237, the Standing Committee is consulted between Day 239 and Day 261, and the Commission adopts the decision by Day 277.

What the 2026 EU pharma package changes

Under the new pharma package (not yet in force), the Commission has 12 days to send a draft decision to the Standing Committee and 12 days from that committee's opinion to decide; see the new pharmaceutical regulation.

Commission decision: common questions

How long after the CHMP opinion does the Commission decide?

About 67 days in the standard timetable. The time covers the transmission of the opinion, the Commission's draft decision, the 22 days Member States have to comment through the Standing Committee and the final adoption. The translations of the product information are prepared and checked in the first weeks of that period.

Is a positive CHMP opinion the same as a marketing authorisation?

No. The opinion is EMA's scientific recommendation. The authorisation exists only once the European Commission has adopted its decision and notified the holder, and the product cannot be placed on the market before then. The Commission normally follows the opinion and must give detailed reasons if its draft decision differs.

Where are Commission decisions on medicines published?

In the Union Register of medicinal products on the Commission's website, which lists each centrally authorised product with its number, its decisions, the annexed product information and the date of notification. A notification of each authorisation also appears in the Official Journal, and EMA publishes the European public assessment report.

Guides that cover Commission decision

Sources

  1. EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use
  2. European Medicines Agency: Pre-authorisation guidance for users of the centralised procedure
  3. European Commission: Union Register of medicinal products

Put your Commission decision question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.